JP2017505784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505784A5 JP2017505784A5 JP2016550815A JP2016550815A JP2017505784A5 JP 2017505784 A5 JP2017505784 A5 JP 2017505784A5 JP 2016550815 A JP2016550815 A JP 2016550815A JP 2016550815 A JP2016550815 A JP 2016550815A JP 2017505784 A5 JP2017505784 A5 JP 2017505784A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disease
- asthma
- compound according
- combination product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000013066 combination product Substances 0.000 claims 9
- 229940127555 combination product Drugs 0.000 claims 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 6
- 208000015943 Coeliac disease Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000002691 Choroiditis Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 208000011231 Crohn disease Diseases 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 4
- 206010022941 Iridocyclitis Diseases 0.000 claims 4
- 208000003971 Posterior uveitis Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 201000004612 anterior uveitis Diseases 0.000 claims 4
- 206010023332 keratitis Diseases 0.000 claims 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 4
- 201000007407 panuveitis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010003694 Atrophy Diseases 0.000 claims 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000001344 Macular Edema Diseases 0.000 claims 3
- 206010025415 Macular oedema Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 206010006451 bronchitis Diseases 0.000 claims 3
- 208000029771 childhood onset asthma Diseases 0.000 claims 3
- 208000007451 chronic bronchitis Diseases 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 230000000968 intestinal effect Effects 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 201000010230 macular retinal edema Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 201000009890 sinusitis Diseases 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229950004244 laninamivir Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003149 muscarinic antagonist Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 claims 1
- 229960002194 oseltamivir phosphate Drugs 0.000 claims 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims 1
- 229960001084 peramivir Drugs 0.000 claims 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229960001028 zanamivir Drugs 0.000 claims 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940282P | 2014-02-14 | 2014-02-14 | |
| US61/940,282 | 2014-02-14 | ||
| US201461941064P | 2014-02-18 | 2014-02-18 | |
| US61/941,064 | 2014-02-18 | ||
| PCT/EP2015/053151 WO2015121444A1 (en) | 2014-02-14 | 2015-02-13 | Aromatic heterocyclic compounds as antiinflammatory compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019220267A Division JP6841891B2 (ja) | 2014-02-14 | 2019-12-05 | 抗炎症化合物としての芳香族複素環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505784A JP2017505784A (ja) | 2017-02-23 |
| JP2017505784A5 true JP2017505784A5 (enExample) | 2018-03-22 |
| JP6630280B2 JP6630280B2 (ja) | 2020-01-15 |
Family
ID=52573661
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550815A Active JP6630280B2 (ja) | 2014-02-14 | 2015-02-13 | 抗炎症化合物としての芳香族複素環化合物 |
| JP2016551294A Active JP6586098B2 (ja) | 2014-02-14 | 2015-02-13 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019162164A Active JP6952085B2 (ja) | 2014-02-14 | 2019-09-05 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019220267A Active JP6841891B2 (ja) | 2014-02-14 | 2019-12-05 | 抗炎症化合物としての芳香族複素環化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551294A Active JP6586098B2 (ja) | 2014-02-14 | 2015-02-13 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019162164A Active JP6952085B2 (ja) | 2014-02-14 | 2019-09-05 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019220267A Active JP6841891B2 (ja) | 2014-02-14 | 2019-12-05 | 抗炎症化合物としての芳香族複素環化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9884845B2 (enExample) |
| EP (4) | EP3105222B1 (enExample) |
| JP (4) | JP6630280B2 (enExample) |
| KR (1) | KR102413704B1 (enExample) |
| CN (4) | CN110522731B (enExample) |
| AU (3) | AU2015216705B2 (enExample) |
| BR (1) | BR112016015838B1 (enExample) |
| CA (1) | CA2938924C (enExample) |
| DK (2) | DK3357919T3 (enExample) |
| EA (1) | EA034927B1 (enExample) |
| ES (2) | ES2774249T3 (enExample) |
| JO (1) | JO3392B1 (enExample) |
| MX (2) | MX371353B (enExample) |
| PL (2) | PL3357919T3 (enExample) |
| PT (2) | PT3105222T (enExample) |
| SG (1) | SG11201607058PA (enExample) |
| TR (1) | TR201809072T4 (enExample) |
| TW (2) | TWI751099B (enExample) |
| UY (1) | UY35998A (enExample) |
| WO (2) | WO2015121660A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| CN104945401B (zh) | 2010-02-01 | 2017-09-05 | 癌症研究技术有限公司 | Ip化合物及它们在治疗中的应用 |
| KR102057058B1 (ko) | 2011-10-03 | 2019-12-18 | 레스피버트 리미티드 | P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| AU2014246866B2 (en) | 2013-04-02 | 2018-05-10 | Oxular Acquisitions Limited | Kinase inhibitor |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| CA2938924C (en) * | 2014-02-14 | 2023-01-31 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| CN105801486A (zh) * | 2016-03-31 | 2016-07-27 | 常州大学 | 一种1-（2,4二溴苯基）-3-吡唑醇的合成方法 |
| WO2017174995A1 (en) | 2016-04-06 | 2017-10-12 | Respivert Limited | Kinase inhibitors |
| AU2017281222B2 (en) * | 2016-06-23 | 2022-06-16 | The Usa As Represented By The Department Of Veterans Affairs; Dept. Of Veterans Affairs Office Of General Counsel - Pag Iv (024) | Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR20200067170A (ko) | 2017-10-05 | 2020-06-11 | 풀크럼 쎄러퓨틱스, 인코포레이티드 | FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2020118194A1 (en) | 2018-12-07 | 2020-06-11 | University Of Maryland, Baltimore | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS |
| CN113498352A (zh) * | 2019-01-23 | 2021-10-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪 |
| JP7495526B2 (ja) | 2020-05-18 | 2024-06-04 | ジーニー ライフサイエンシズ インコーポレイテッド | Ｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 |
| CN111889025B (zh) * | 2020-09-01 | 2022-01-11 | 山东大学 | 一种耐酸碱耐盐超两亲分子乳化剂及其制备方法和乳液 |
| JP2023546835A (ja) | 2020-10-29 | 2023-11-08 | ジーニー ライフサイエンシズ インコーポレイテッド | 結晶性５－（ジメチルアミノ）－ｎ－（４－（モルホリノメチル）フェニル）ナフタレン－１－スルホンアミド二塩酸塩二水和物 |
| AU2022215580A1 (en) * | 2021-02-03 | 2023-08-10 | Bp Asset V, Inc. | Formulation of furin inhibitor for inhalation |
| AU2022244224B9 (en) * | 2021-03-23 | 2025-01-30 | Gen1E Lifesciences Inc. | Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors |
| CN116655608B (zh) * | 2023-05-30 | 2025-08-19 | 成都瑞芬思德丹生物科技有限公司 | 一种具有抗炎活性的吡咯烷酮类化合物及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032110A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| SK285371B6 (sk) | 1997-12-22 | 2006-12-07 | Bayer Corporation | Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom |
| US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| WO2001004115A2 (en) | 1999-07-09 | 2001-01-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
| ATE375334T1 (de) | 1999-11-16 | 2007-10-15 | Boehringer Ingelheim Pharma | Harnstoff derivate als entzündungshemmende mittel |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| AU2001245353A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| DE60219793T2 (de) | 2001-07-11 | 2008-01-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen |
| PT1478358E (pt) | 2002-02-11 | 2013-09-11 | Bayer Healthcare Llc | Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| DE60319066T2 (de) | 2002-02-25 | 2009-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
| MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| ES2357288T3 (es) | 2003-02-28 | 2011-04-25 | Bayer Healthcare Llc | Derivados de 2-oxo-1,3,5-perhidrotriazapina útiles en el tratamiento de angiogénesis hiperproliferativa y trastornos inflamatorios. |
| MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
| GB0500435D0 (en) | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| US7700620B2 (en) | 2005-06-27 | 2010-04-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| JP2010506942A (ja) | 2006-10-20 | 2010-03-04 | イコス・コーポレイション | Ｃｈｋ１阻害剤の組成物 |
| SG10201608813PA (en) | 2008-03-17 | 2016-12-29 | Ambit Biosciences Corp | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| WO2010038086A2 (en) | 2008-10-02 | 2010-04-08 | Respivert Limited | Novel compounds |
| NZ593104A (en) * | 2008-12-11 | 2012-11-30 | Respivert Ltd | P38 map kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| CN103804295B (zh) | 2010-03-15 | 2016-11-23 | 宇部兴产株式会社 | 制备酰胺化合物的方法 |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787976B2 (ja) * | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤としてのピラゾリルウレア |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| JP5973426B2 (ja) | 2010-06-17 | 2016-08-23 | レスピバート・リミテツド | Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤 |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| KR102057058B1 (ko) | 2011-10-03 | 2019-12-18 | 레스피버트 리미티드 | P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PT2788349T (pt) | 2011-12-09 | 2017-02-02 | Chiesi Farm Spa | Inibidores de cinase |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| AU2014246866B2 (en) | 2013-04-02 | 2018-05-10 | Oxular Acquisitions Limited | Kinase inhibitor |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| WO2015092423A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| CA2938924C (en) | 2014-02-14 | 2023-01-31 | Respivert Limited | Pyrazolyl-ureas as kinase inhibitors |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| US20170209445A1 (en) | 2014-10-01 | 2017-07-27 | Respivert Limited | Kinase inhibitors |
-
2015
- 2015-02-13 CA CA2938924A patent/CA2938924C/en active Active
- 2015-02-13 SG SG11201607058PA patent/SG11201607058PA/en unknown
- 2015-02-13 PT PT157057977T patent/PT3105222T/pt unknown
- 2015-02-13 EA EA201691625A patent/EA034927B1/ru unknown
- 2015-02-13 EP EP15705797.7A patent/EP3105222B1/en active Active
- 2015-02-13 WO PCT/GB2015/050401 patent/WO2015121660A1/en not_active Ceased
- 2015-02-13 PT PT181618695T patent/PT3357919T/pt unknown
- 2015-02-13 ES ES18161869T patent/ES2774249T3/es active Active
- 2015-02-13 JP JP2016550815A patent/JP6630280B2/ja active Active
- 2015-02-13 US US15/118,708 patent/US9884845B2/en active Active
- 2015-02-13 PL PL18161869T patent/PL3357919T3/pl unknown
- 2015-02-13 CN CN201910753454.9A patent/CN110522731B/zh active Active
- 2015-02-13 MX MX2016010572A patent/MX371353B/es active IP Right Grant
- 2015-02-13 EP EP18161869.5A patent/EP3357919B1/en active Active
- 2015-02-13 EP EP15706511.1A patent/EP3105223B1/en active Active
- 2015-02-13 AU AU2015216705A patent/AU2015216705B2/en active Active
- 2015-02-13 AU AU2015216957A patent/AU2015216957B2/en active Active
- 2015-02-13 WO PCT/EP2015/053151 patent/WO2015121444A1/en not_active Ceased
- 2015-02-13 CN CN201580008529.0A patent/CN106164067B/zh active Active
- 2015-02-13 ES ES15705797.7T patent/ES2677595T3/es active Active
- 2015-02-13 MX MX2016010571A patent/MX371312B/es active IP Right Grant
- 2015-02-13 JP JP2016551294A patent/JP6586098B2/ja active Active
- 2015-02-13 TW TW104104906A patent/TWI751099B/zh active
- 2015-02-13 TW TW104104905A patent/TWI664967B/zh active
- 2015-02-13 US US14/622,368 patent/US9447076B2/en active Active
- 2015-02-13 DK DK18161869.5T patent/DK3357919T3/da active
- 2015-02-13 UY UY0001035998A patent/UY35998A/es active IP Right Grant
- 2015-02-13 TR TR2018/09072T patent/TR201809072T4/tr unknown
- 2015-02-13 CN CN202110516085.9A patent/CN113264921B/zh active Active
- 2015-02-13 EP EP18186182.4A patent/EP3418279B1/en active Active
- 2015-02-13 CN CN201580019810.4A patent/CN106573914B/zh active Active
- 2015-02-13 KR KR1020167023275A patent/KR102413704B1/ko active Active
- 2015-02-13 BR BR112016015838-5A patent/BR112016015838B1/pt active IP Right Grant
- 2015-02-13 DK DK15705797.7T patent/DK3105222T3/en active
- 2015-02-13 PL PL15705797T patent/PL3105222T3/pl unknown
- 2015-02-15 JO JOP/2015/0032A patent/JO3392B1/ar active
-
2016
- 2016-08-31 US US15/253,141 patent/US9624196B2/en active Active
-
2017
- 2017-03-13 US US15/457,810 patent/US10045980B2/en active Active
- 2017-12-21 US US15/849,987 patent/US10294216B2/en active Active
-
2018
- 2018-07-11 US US16/032,858 patent/US10815217B2/en active Active
-
2019
- 2019-03-27 US US16/366,103 patent/US11142515B2/en active Active
- 2019-06-26 AU AU2019204525A patent/AU2019204525B2/en active Active
- 2019-09-05 JP JP2019162164A patent/JP6952085B2/ja active Active
- 2019-12-05 JP JP2019220267A patent/JP6841891B2/ja active Active
-
2020
- 2020-09-24 US US17/031,190 patent/US11634406B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505784A5 (enExample) | ||
| JP2016519680A5 (enExample) | ||
| AU2015214961B2 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| AU2007334402B2 (en) | Methods of using MEK inhibitors | |
| JP4636486B2 (ja) | 脈管形成阻害活性を有するアリール尿素 | |
| JP2017533895A5 (enExample) | ||
| JP5485875B2 (ja) | ピリダジノン誘導体 | |
| AU2014241183B2 (en) | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide derivatives and their use as PHD inhibitors | |
| CA2918813A1 (en) | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases | |
| CA2895404A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
| JP2023501599A (ja) | Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 | |
| EP3541813A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2014525427A5 (enExample) | ||
| WO2015036560A1 (de) | Heterocyclisch substituierte trifluormethylpyrimidinone und ihre verwendung | |
| JP2014512406A5 (enExample) | ||
| JP2014525426A5 (enExample) | ||
| WO2012065057A2 (en) | Phosphatidylinositol 3-kinase inhibitors and methods of their use | |
| CA2917562A1 (en) | Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| TW201726678A (zh) | 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途 | |
| CN110461837B (zh) | 新型吡咯并吡啶衍生物、其制备方法及用途 | |
| IL296182A (en) | Inhibitors of human immunodeficiency virus replication | |
| EP3679029A1 (en) | Imidazolidine compounds | |
| RU2013152961A (ru) | Изоксазолины в качестве терапевтических агентов | |
| JP2019514861A5 (enExample) |